An Update on COVID ‐19 Associated Mucormycosis Characteristics, Risk Factors, and Outcomes: a Systematic Review and Meta-Analysis

AbstractPurpose of ReviewThis meta-analysis aimed to identify the CAM manifestations, clinical presentations, relevant risk factors, mortality risk factors, treatments, outcomes, and survival.Recent FindingsCOVID-19-associated mucormycosis (CAM) increased dramatically, with mucormycosis development estimated to be 50 times higher than before the COVID-19 pandemic. CAM is a high-mortality disease with significant morbidities in survivors. A significant association between uncontrolled diabetes and CAM has been indicated. In addition, high-dose corticosteroid therapy and ICU admission were present in many rhino-orbito-cerebral mucormycosis (ROCM) patients and non-ROCM, respectively. In the present study, we systematically searched PubMed, Scopus, WoS, and PMC, preprint databases, and the reference lists of the included relevant studies until Oct 2021. Studies that report mucormycosis cases (proven/probable) with individual patient details with confirmed COVID-19 infection were included according to the PRISMA statement. Pooling data of 210 CAM patients (proven, 87.6%; probable, 12.4%) was retrieved from 60 case reports/series studies from 17 countries.SummaryPrimary or corticosteroid-induced diabetes was the leading independent risk factor for rhino-maxillo-orbito-cerebral mucormycosis (RMOCM) development (OR:18.29). In contrast, ICU admission was the main independent risk factor for non-RMOCM development (OR:11.64). In the absence of the mentioned risk factors, the risk of CAM...
Source: Current Fungal Infection Reports - Category: Infectious Diseases Source Type: research